Sunday, April 12, 2026, San Juan, Puerto Rico, 1:30 PM – 3:00 PM Atlantic Standard Time (UTC-4)

Data + Perspectives: The Potential Role of TROP2- and CDH6-Directed Antibody-Drug Conjugates in Gynecologic Cancers

An Independent CME Symposium During the 2026 SGO Annual Meeting on Women’s Cancer®

Register for in-person Register for webcast

Program Schedule — Atlantic Standard Time (UTC-4)
1:00 PM – 1:30 PM — Registration and Lunch Buffet
1:30 PM – 3:00 PM — Educational Meeting

Location
Puerto Rico Convention Center
100 Convention Boulevard
San Juan, Puerto Rico
Phone: +1 (787) 641-7722

Meeting Room
Room 209 (Level 2)

No registration fee is charged for this event. For the in-person symposium in San Juan, preregistration is required as seating is limited.  
 
Faculty
Ramez N Eskander, MD
Julie St John Endowed Chair
in Gynecologic Oncology
Professor, Department of Obstetrics, Gynecology and Reproductive Sciences
Clinical Trials Office Medical Director
Fellowship Director – Gynecologic Oncology
UC San Diego Health
Rebecca and John Moores NCI-Designated Comprehensive Cancer Center
San Diego, California

Bradley J Monk, MD
Medical Director, Late-Phase Research Program
Florida Cancer Specialists & Research Institute
Professor at the University of Central Florida College of Medicine
Vice President and Member, Board of Directors
GOG Foundation
Co-Director, GOG Partners
West Palm Beach, Florida
Moderator
Kathleen N Moore, MD, MS
Deputy Director and Director
Phase 1 Clinical Trials
Fred and Pamela Buffett Cancer Center
at the University of Nebraska
Omaha, Nebraska



This activity is supported by educational grants from Daiichi Sankyo Inc, Gilead Sciences Inc, and Merck.
Program Schedule — Atlantic Standard Time (UTC-4)
1:00 PM – 1:30 PM — Registration and Lunch Buffet
1:30 PM – 3:00 PM — Educational Meeting

MODULE 1: Advances in Human Cadherin-6 (CDH6)-Targeted Antibody-Drug Conjugates (ADCs) for Ovarian and Other Gynecologic Cancers

  • Rationale for targeting CDH6 in advanced ovarian cancer (OC); mechanism of antitumor activity of raludotatug deruxtecan (R-DXd)
  • Available research findings with R-DXd for patients with heavily pretreated platinum-resistant advanced OC
  • FDA breakthrough therapy designation for R-DXd for patients with platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancers expressing CDH6 who have received prior treatment with bevacizumab
  • Design, eligibility criteria, key primary and secondary endpoints, and preliminary data of the Phase II/III REJOICE-Ovarian01 trial of R-DXd for platinum-resistant advanced OC; estimated completion date
  • Future development plans for R-DXd in other settings; Phase I data for platinum-sensitive advanced OC and ongoing evaluation for endometrial cancer (EC), cervical cancer (CC) and nonhigh-grade serous OC in the Phase II REJOICE-PanTumor01 study
  • Other CDH6-targeted ADCs under investigation for advanced gynecologic cancers

MODULE 2: Leveraging TROP2-Directed ADCs in the Treatment of Advanced Gynecologic Cancers

  • Biological rationale for the evaluation of TROP2-directed ADCs for advanced gynecologic cancers
  • Mechanistic similarities and differences among sacituzumab govitecan, datopotamab deruxtecan (Dato-DXd) and sacituzumab tirumotecan (sac-TMT); implications for efficacy and tolerability
  • Preliminary efficacy findings reported with sacituzumab govitecan, Dato-DXd and sac-TMT, respectively, for patients with pretreated advanced EC
  • Early efficacy outcomes documented with TROP2-directed ADCs for patients with advanced OC
  • Preclinical and early clinical trial data with TROP2-targeted ADCs for advanced CC
  • Design, eligibility criteria and primary and secondary endpoints of ongoing Phase III trials evaluating TROP2-directed ADCs for advanced gynecologic cancers; estimated completion dates

MODULE 3: Tolerability and Other Practical Considerations with Novel Investigational ADCs for Advanced Gynecologic Cancers

  • Spectrum, frequency and severity of toxicities reported with R-DXd in patients with advanced OC
  • Tolerability profiles of sacituzumab govitecan, Dato-DXd and sac-TMT in early clinical trials for advanced gynecologic cancers
  • Appropriate strategies to monitor for, mitigate and manage toxicities with R-DXd and TROP2-directed ADCs
  • Relationship between level of CDH6 and TROP2 expression and outcomes in early research efforts with ADCs targeting these proteins; role, if any, of assessment of these biomarkers in treatment for patients with gynecologic tumors
  • Published data exploring the mechanisms of resistance to ADCs and the feasibility of sequencing these agents; potential impact on the future use of R-DXd and TROP2-targeted ADCs in therapy for advanced gynecologic cancers

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand the structural components and mechanisms of action of novel antibody-drug conjugates (ADCs) under investigation for gynecologic cancers.
  • Appreciate the incidence of cadherin-6 expression in gynecologic cancers, and consider available research findings with and the potential of novel ADCs targeting this newly emerging biomarker.
  • Recognize the biological rationale for and available data with TROP2-directed ADCs for patients with gynecologic cancers, and consider the potential role of these agents in disease treatment.
  • Compare and contrast the toxicities associated with novel ADCs under development for patients with gynecologic cancers, and appreciate available supportive management strategies to minimize or ameliorate these side effects.
  • Understand the mechanisms of resistance to available and emerging ADCs, and evaluate the impact this information may have on optimal selection and sequencing of therapies.
  • Recall the design of ongoing clinical trials evaluating novel ADCs for gynecologic cancers, and appropriately counsel patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Eskander — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Foundation Medicine, Gilead Sciences Inc, GSK, ImmunoGen Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MSD, Myriad Genetic Laboratories Inc, Natera Inc, Novocure Inc, Pfizer Inc, pharmaand GmbH, PMV Pharma, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Data and Safety Monitoring Boards/Committees: Xencor. Dr Monk — Consulting Agreements: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, BioNTech SE, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Mersana Therapeutics Inc, Mural Oncology Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, OncoC4, Panavance Therapeutics, Pfizer Inc, pharmaand GmbH, ProfoundBio, Regeneron Pharmaceuticals Inc, Seagen Inc, Sutro Biopharma, Takeda Pharmaceuticals USA Inc, Tubulis, Verastem Inc, Zai Lab, Zentalis Pharmaceuticals, Zymeworks Inc; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, ImmunoGen Inc, Merck, Takeda Pharmaceuticals USA Inc, Zai Lab.

MODERATOR — Dr Moore — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, Mersana Therapeutics Inc; Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, GSK, ImmunoGen Inc, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Whitehawk Therapeutics, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Accent Therapeutics, Advaxis Inc, Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, Immunocore, Iovance Biotherapeutics, Regeneron Pharmaceuticals Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics; Nonrelevant Financial Relationships: ASCO, GOG Partners, NRG Oncology.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Daiichi Sankyo Inc, Gilead Sciences Inc, and Merck.

Puerto Rico Convention Center
100 Convention Boulevard
San Juan, Puerto Rico 00907
Phone: +1 (787) 641-7722

Meeting Room
Room 209 (Level 2)

Directions
The Puerto Rico Convention Center is the main venue for the 2026 SGO Annual Meeting on Women’s Cancer.

 
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

No registration fee is charged for this event. At this time in-person registration for this educational activity is limited to practicing clinicians actively caring for patients with cancer. For all other professionals, including industry personnel,* we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you.

NOTICE
Registration for this event is independent of registration for the 2026 SGO Annual Meeting on Women’s Cancer.

IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
STANDBY IN-PERSON registration for other/industry professionals*

If you would like to stand by for participation in this event, please provide your contact information here. We will notify you if seats become available. You are welcome to attend virtually — please register below with the WEBCAST option.

STANDBY IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.